Literature DB >> 11706064

Effect of naturally occurring E2F-4 alterations on transcriptional activation and proliferation in transfected cells.

H Takashima1, Y Matsumoto, N Matsubara, Y Shirakawa, R Kawashima, M Tanino, S Ito, H Isozaki, M Ouchida, S J Meltzer, K Shimizu, N Tanaka.   

Abstract

E2F is a family of transcription factors implicated in the regulation of gene expression required for progression through the G(1)-S transition. We have previously detected tumor-specific mutations at a trinucleotide repeat coding sequence of E2F-4 gene in a subset of human sporadic colorectal cancers. The purpose of this study was to investigate the potential functional consequences of these E2F-4 mutations. We transfected NIH3T3 fibroblasts with expression constructs containing wild-type as well as mutant E2F-4 cDNA, and the effect of the E2F-4 mutations on proliferation was examined. Alteration in transactivation of the E2F consensus promoter sequence was also examined by transient cotransfection of a E2F-4 with a DP-2 construct into cultured human cells. Transfected cell clones overexpressing mutant E2F-4 grew more rapidly and showed higher proliferative activity by increased immunohistochemical staining for proliferating cell nuclear antigen (PCNA). All three mutant forms of E2F-4 showed elevated transactivation of the E2F consensus promoter sequence. Thus, expression of mutant E2F-4s confers a growth advantage in vivo, and this effect may be related to the acquisition of a neoplastic phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11706064     DOI: 10.1038/labinvest.3780370

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  1 in total

1.  A screening of a library of T7 phage-displayed peptide identifies E2F-4 as an etoposide-binding protein.

Authors:  Mihoko Takami; Yoichi Takakusagi; Kouji Kuramochi; Senko Tsukuda; Satoko Aoki; Kengo Morohashi; Keisuke Ohta; Susumu Kobayashi; Kengo Sakaguchi; Fumio Sugawara
Journal:  Molecules       Date:  2011-05-24       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.